m5C: Novel Diagnostic and Drug Repurposing Targets for Nonalcoholic Steatohepatitis
International Journal of Genomics · 2026-01 · 2026 (1)
DOI: 10.1155/ijog/4309290 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Genomics, online erschienen am 25.02.2026. Verfasst von Shuxian Chen und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Xiangyang No.1 People's Hospital, Hubei University of Medicine, Xiangyang, China, hbmu.edu.cn. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Epigenetic medication, such as RNA 5‐methylcytosine (m5C), is well‐recognized as a key regulator in hepatic metabolism and immune responses. However, m5C regulatory mechanisms in NASH pathogenesis have not yet been clearly elucidated.
Methods
By utilizing three bulk profiles of NASH patients acquired from GEO and integrative bioinformatic pipelines, such as Limma framework, consensus clustering, and machine learning, we first identified m5C‐related molecular subgroups and hub genes for NASH patients. Besides, diagnostic performance and biological characteristics of m5C‐related hub gene were estimated at bulk level. Indeed, the heterogeneity of m5C‐related hub gene for NASH patients was deciphered in single‐cell transcriptomic profiles at temporal and spatial manners, especially in artificial intelligence (AI)‐driven virtual cells. Furthermore, potential therapeutic agents targeting m5C‐associated hub genes for the treatment of NASH were enriched by AI‐driven drug enrichment framework (DrugReflector) based on NASH bulk profile and then validated by molecular docking. Finally, in vitro studies quantified the expression of m5C‐associated hub genes compared to normal control. Results m5C can divide NASH patients into two various consensus groups with different molecular and immune patterns. Furthermore, ERCC2 and FOXC2 can be considered two upregulated m5C‐associated hub genes involved in NASH pathogenesis, which were mainly distributed at cholangiocyte. BRD‐K93672499 can be considered a multitarget therapeutic strategy targeting ERCC2 and FOXC2 for the treatment of NASH.
Conclusion
Our study first deciphered the m5C in predictive and therapeutic potential for NASH patients, which gains more insight into their personalized and precision medicine.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Gastroenterology, Xiangyang No.1 People's Hospital, Hubei University of Medicine, Xiangyang, China, hbmu.edu.cn.
- Department of General Surgery, Zaoyang No.1 People's Hospital, Zaoyang, China.
- The Fourth Clinical College of Hubei University of Medicine, Shiyan, China.
Zitieren
APA
Chen, S., Duan, R., Qiu, J., Lei, Z., Chen, W., & Li, X. (2026). m5C: Novel Diagnostic and Drug Repurposing Targets for Nonalcoholic Steatohepatitis. International Journal of Genomics, 2026(1). https://doi.org/10.1155/ijog/4309290
Vancouver
Chen S, Duan R, Qiu J, Lei Z, Chen W, Li X. m5C: Novel Diagnostic and Drug Repurposing Targets for Nonalcoholic Steatohepatitis. International Journal of Genomics. 2026;2026(1). doi:10.1155/ijog/4309290
BibTeX
@article{Chen2026,
author = {Chen, Shuxian and Duan, Renquan and Qiu, Jingyi and Lei, Zhiyu and Chen, Wei and Li, Xiumei},
title = {m5C: Novel Diagnostic and Drug Repurposing Targets for Nonalcoholic Steatohepatitis},
journal = {International Journal of Genomics},
year = {2026},
volume = {2026},
number = {1},
doi = {10.1155/ijog/4309290}
}
EUVIMED